Faculty

Keith H. Baratz, M.D.

Clinical Studies

Hereditary Eye Disease Study Rochester, Minn.
The purpose of this study is to learn more about eye diseases that run in families.

A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing The Efficacy And Safety Of STN1010904 Ophthalmic Suspension 0.03% And 0.1% Compared With Vehicle In Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study Rochester, Minn.
The purpose of this study is to assess the effectiveness and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing, when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period.
Evaluation of the Clinical and Genetic association between Myotonic Dystrophy Type 1 and Fuchs Endothelial Corneal Dystrophy Rochester, Minn.
The purpose of this study is to test for a clinical and genetic association between Myotonic Dystrophy Type 1 (DM1) and Fuchs endothelial corneal dystrophy (FECD).
Long-term Suppressive Valacyclovir Treatment For Herpes Zoster Ophthalmicus Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
This is a multi-center, randomized, double-masked, placebo-controlled clinical trial of suppressive valacyclovir for one year in immunocompetent study participants with an episode of dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis due to Herpes Zoster Ophthalmicus (HZO) in the year prior to enrollment.